Summary
The product Arimidex Anastrozole, manufactured by Vulkan Pharmaceuticals, underwent independent testing to verify its authenticity and potency. The sample, identified by batch number 2LT54E, was submitted by the manufacturer VulkanPharma and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Anastrozole, with a concentration of 0.99 mg per pill, which is 1% below the labeled claim of 1 mg.
The testing process was conducted on 13 November 2024. The results indicate a slight underdosing, which is within an acceptable margin of error. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Vulkan Pharmaceuticals
- Product Name: Arimidex Anastrozole
- Active Ingredient: Anastrozole
- Batch Number: 2LT54E
- Expiration Date: Not provided
- Delivery Method: Oral
Sample Acquisition and Testing
- Task Number: #52517
- Testing Ordered: 29 OCT 2024
- Sample Received: 05 NOV 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Vulkan Pharmaceuticals (Manufacturer)
- Analysis Paid For By: Vulkan Pharmaceuticals (Manufacturer)
Testing Results
- Specification: 1 mg per pill (as stated on the label)
- Measured Concentration: 0.99 mg per pill
- Accuracy: 99% (1% below the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/52517_79W8AM4GC397
Evaluation of Manufacturer-Submitted Testing
This analysis highlights a minor underdosing issue with the tested product. The sample was submitted and funded by the manufacturer VulkanPharma, which may introduce potential biases. Vanufacturer often select optimal batches for testing, which may not fully represent the consistency of products available to consumers. While Janoshik Analytical is recognized for its transparency and rigorous testing protocols, these findings would benefit from independent validation through third-party testing across multiple batches.
Conclusion
The analysis confirms that Arimidex Anastrozole is slightly underdosed, with a measured concentration of 0.99 mg per pill. This result is within an acceptable margin of error and reflects relatively strong quality control for this batch. However, it underscores the importance of additional testing to ensure consistent dosing across the product line. This report is provided to support educational and harm reduction efforts, helping consumers make informed choices regarding pharmaceutical products.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-submitted testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
